Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 15/20 | 0.49 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043885 | 0.95 | SREBF2 (0.48) | SREBF2SREBF1CDC7DBF4ALDH1A1 | |
| SCHEMBL5044060 | 0.89 | SREBF2 (0.51) | SREBF2SREBF1CDC7DBF4ALDH1A1 | |
| SCHEMBL5047165 | 0.86 | SREBF2 (0.50) | SREBF2SREBF1CDC7DBF4ALDH1A1 | |
| SCHEMBL5047117 | 0.85 | SREBF2 (0.43) | SREBF2SREBF1CDC7DBF4ALDH1A1 | |
| SCHEMBL5044546 | 0.84 | SREBF2 (0.49) | SREBF2SREBF1CDC7DBF4ALDH1A1 | |
| SCHEMBL5045028 | 0.84 | SREBF2 (0.41) | SREBF2SREBF1ALDH1A1MAPT | |
| SCHEMBL5039349 | 0.84 | SREBF2 (0.48) | SREBF2SREBF1CDC7DBF4ALDH1A1 | |
| SCHEMBL5043694 | 0.83 | EIF4E (0.41) | ALDH1A1MAPTEIF4E | |
| SCHEMBL5044535 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MAPTATMEIF4E | |
| SCHEMBL5040270 | 0.82 | SREBF2 (0.48) | SREBF2SREBF1CDC7DBF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135488-B2 | Pyrrolyl-thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1583762-A1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004060888-A1 | NOVEL CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | CNR1, CNR2, NPY1R | SREBF2 2076/4885SREBF1 1307/4885CDC7 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.